Clinical Trial

Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis). The main questions it aims to answer are: 1. to document the rate of complications associated with combining IRE with immune boosting drugs. 2. After one liver metastasis is treated with IRE and immune boosting drugs, what is the change in the size of the non-IRE-treated liver metastases? 3. What is the immune response (measured in a blood sample) when IRE is combined with one or two types of immune boosting drugs?
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-13.
Trial Details
NCT Number NCT06047015
Lead Sponsor University of Saskatchewan
Conditions Liver Metastasis Colon Cancer
Enrollment 12 participants
Start Date 2025-07
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-09